Drug-induced aortic valve stenosis: An under recognized entity

Area of Science:

• Cardiology
• Pharmacology
• Pathology

Background:

• Aortic stenosis (AS) observed with mitral drug-induced valvular heart disease (DI-VHD) suggests valvulopathic drugs may contribute to AS pathogenesis.
• Investigating the link between valvulopathic drug exposure and the co-occurrence of AS and mitral DI-VHD.

Purpose of the Study:

• To report echocardiographic and pathological findings in patients with AS and mitral DI-VHD after valvulopathic drug exposure.
• To explore the potential role of valvulopathic drugs in AS development.

Main Methods:

• Retrospective analysis of 25 patients with AS (mean gradient >15mmHg) and mitral DI-VHD.
• Exclusion of patients with rheumatic fever, radiation therapy, systemic disease, or bicuspid aortic valve.
• Echocardiographic and pathological examination of aortic and mitral valves.

Main Results:

• 25 patients (mean age 62) presented with AS and mitral DI-VHD.
• Aortic regurgitation was present in 96% of patients; 68% had prior diagnosis of drug-induced aortic regurgitation.
• Pathology revealed dense, non-inflammatory fibrosis in aortic valves, characteristic of DI-VHD.

Conclusions:

• The association between AS and mitral DI-VHD following valvulopathic drug exposure is significant.
• Valvulopathic drugs may play a role in the pathogenesis of AS, evidenced by fibrotic changes in aortic valves.